{"id":"buprenorphine-lo","safety":{"commonSideEffects":["nausea","constipation","headache","dizziness","somnolence"],"contraindications":["hypersensitivity to buprenorphine"]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Mu-opioid receptor","explanation":"As a partial mu-opioid receptor agonist, buprenorphine produces analgesic effects and reduces opioid cravings while having a ceiling effect that limits respiratory depression. Its high receptor affinity and slow dissociation contribute to prolonged duration of action.","oneSentence":"Buprenorphine acts as a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors."},"_scrapedAt":"2026-03-28T05:44:39.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123225,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"methadone","brand":"Dolophine","company":null,"rationale":"Full opioid agonist used for opioid use disorder and pain management"},{"name":"naltrexone","brand":"Vivitrol","company":"Alkermes","rationale":"Opioid antagonist for opioid use disorder treatment"},{"name":"morphine","brand":null,"company":null,"rationale":"Standard opioid analgesic for moderate to severe pain"}],"description":"Buprenorphine LO is an investigational formulation of buprenorphine currently in Phase 1 clinical development. Buprenorphine is a partial opioid agonist with established use in pain management and opioid use disorder treatment. This specific formulation's therapeutic target and intended indication remain undisclosed at this early stage.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT01296334","phase":"NA","title":"Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine","status":"COMPLETED","sponsor":"mads u werner","startDate":"2011-02","conditions":"Pain","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Temgesic"],"phase":"phase_1","status":"active","brandName":"Buprenorphine LO","genericName":"Buprenorphine LO","companyName":"mads u werner","companyId":"mads-u-werner","firstApprovalDate":"","aiSummary":"Buprenorphine LO is a small molecule that acts as a mu opioid receptor agonist. It is used to treat pain, as indicated by clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}